174 related articles for article (PubMed ID: 36260562)
1. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
Li X; Moreira DC; Bag AK; Qaddoumi I; Acharya S; Chiang J
Neuro Oncol; 2023 Apr; 25(4):750-760. PubMed ID: 36260562
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.
Pathak P; Kumar A; Jha P; Purkait S; Faruq M; Suri A; Suri V; Sharma MC; Sarkar C
Brain Pathol; 2017 Sep; 27(5):580-589. PubMed ID: 27608415
[TBL] [Abstract][Full Text] [Related]
3. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T
Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790
[TBL] [Abstract][Full Text] [Related]
4. Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system.
Reis GF; Bloomer MM; Perry A; Phillips JJ; Grenert JP; Karnezis AN; Tihan T
Mod Pathol; 2013 Oct; 26(10):1279-87. PubMed ID: 23702730
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
[TBL] [Abstract][Full Text] [Related]
6. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
[TBL] [Abstract][Full Text] [Related]
7. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F
PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.
Rodriguez EF; Scheithauer BW; Giannini C; Rynearson A; Cen L; Hoesley B; Gilmer-Flynn H; Sarkaria JN; Jenkins S; Long J; Rodriguez FJ
Acta Neuropathol; 2011 Mar; 121(3):407-20. PubMed ID: 21113787
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract][Full Text] [Related]
10. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.
Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST
J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326
[TBL] [Abstract][Full Text] [Related]
11. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity.
Sadighi Z; Slopis J
J Child Neurol; 2013 May; 28(5):625-32. PubMed ID: 23439714
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of disseminated pilocytic astrocytomas.
Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
[TBL] [Abstract][Full Text] [Related]
13. Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors.
Lee RP; Foster KA; Lillard JC; Klimo P; Ellison DW; Orr B; Boop FA
J Neurosurg Pediatr; 2017 Sep; 20(3):247-255. PubMed ID: 28686121
[TBL] [Abstract][Full Text] [Related]
14. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours.
Jacob K; Albrecht S; Sollier C; Faury D; Sader E; Montpetit A; Serre D; Hauser P; Garami M; Bognar L; Hanzely Z; Montes JL; Atkinson J; Farmer JP; Bouffet E; Hawkins C; Tabori U; Jabado N
Br J Cancer; 2009 Aug; 101(4):722-33. PubMed ID: 19603027
[TBL] [Abstract][Full Text] [Related]
15. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
[TBL] [Abstract][Full Text] [Related]
16. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
17. BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum.
Faulkner C; Ellis HP; Shaw A; Penman C; Palmer A; Wragg C; Greenslade M; Haynes HR; Williams H; Lowis S; White P; Williams M; Capper D; Kurian KM
J Neuropathol Exp Neurol; 2015 Sep; 74(9):867-72. PubMed ID: 26222501
[TBL] [Abstract][Full Text] [Related]
18. Rare adult pilocytic astrocytoma of the septum pellucidum with novel RIN2::BRAF fusion.
Liu X; Dai X; Dai C; Zhu Q; Chen A; Chen Y; Chen N; Chen P; Rong R; Shi C; Xiao S; Dong J
Virchows Arch; 2023 Feb; 482(2):445-450. PubMed ID: 36520196
[TBL] [Abstract][Full Text] [Related]
19. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
Hütt-Cabezas M; Karajannis MA; Zagzag D; Shah S; Horkayne-Szakaly I; Rushing EJ; Cameron JD; Jain D; Eberhart CG; Raabe EH; Rodriguez FJ
Neuro Oncol; 2013 Dec; 15(12):1604-14. PubMed ID: 24203892
[TBL] [Abstract][Full Text] [Related]
20. Pilocytic astrocytoma vs. ganglioglioma: Progression vs. misdiagnosis, and implications in BRAF testing.
Yoon J; Cusimano M; Munoz DG
J Clin Neurosci; 2019 Aug; 66():231-234. PubMed ID: 31147230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
